Gilead Sciences, Inc.
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Restructuring expenses by Year
Restructuring expenses — Research and development ($M) ($M)
Gilead Sciences Restructuring expenses: $68M in FY2025, down 30.6% from a year earlier.
Latest, FY2025
68
Period ended Dec 31, 2025
Change on a year earlier
-30.6%
98 in FY2024
History
3 years
Since FY2023
Sources
1
Form 10-K (filed 2026-02-24)
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Restructuring Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Restructuring expenses — Research and development ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 68 | -30.6% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 98 | +390.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 20 | – | Form 10-K (filed 2026-02-24) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Restructuring expenses ($M), annual FY2023–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/restruct-exp-rd
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.